Abstract
Summary
ADCs are mainly composed of three parts: antibodies, linkers, and cytotoxic loads. They are a type of bioactive cytotoxic drugs that are linked to monoclonal antibodies through chemical bonds and use monoclonal antibodies as carriers to target and transport cytotoxic drugs to target cells. Complex that works. The design concept of ADC was first proposed by Paul Ehrlich in the early 20th century. In 2000, the U.S. Food and Drug Administration (FDA) approved the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), for the treatment of acute myeloid myelopathy in adults. Leukemic cell lines, marking the beginning of the era of ADC-targeted cancer therapy.
The global market for Antibody Drug Conjugates Contract Manufacturing was estimated to be worth US$ 2827.3 million in 2023 and is forecast to a readjusted size of US$ 9332.5 million by 2030 with a CAGR of 18.9% during the forecast period 2024-2030.
Key global companies of Antibody Drug Conjugates Contract Manufacturing (ADC) include Lonza, Merck, Recipharm, Thermo Fisher, AbbVie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions and Curia. The top three players are Lonza, Merck and Recipharm, which together account for about 50% of the global market share. The largest player is Lonza Group. From the production side, the global players are mainly concentrated in North America and Europe. North America accounts for about 35% of the global market share. In terms of type, IgG1 dominates the global antibody drug conjugate contract manufacturing market. In terms of application, solid tumor applications account for more than half of the market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugates Contract Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugates Contract Manufacturing.
The Antibody Drug Conjugates Contract Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugates Contract Manufacturing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugates Contract Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Lonza Group
Merck KGaA
Recipharm
Thermo Fisher Scientific
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Curia
Novasep
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
Segment by Type
IgG1
IgG4
Segment by Application
Solid Tumors
Hematological Malignancies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Antibody Drug Conjugates Contract Manufacturing in global and regional level.
Chapter 3: Detailed analysis of Antibody Drug Conjugates Contract Manufacturing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody Drug Conjugates Contract Manufacturing revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
The global market for Antibody Drug Conjugates Contract Manufacturing was estimated to be worth US$ 2827.3 million in 2023 and is forecast to a readjusted size of US$ 9332.5 million by 2030 with a CAGR of 18.9% during the forecast period 2024-2030.
Key global companies of Antibody Drug Conjugates Contract Manufacturing (ADC) include Lonza, Merck, Recipharm, Thermo Fisher, AbbVie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions and Curia. The top three players are Lonza, Merck and Recipharm, which together account for about 50% of the global market share. The largest player is Lonza Group. From the production side, the global players are mainly concentrated in North America and Europe. North America accounts for about 35% of the global market share. In terms of type, IgG1 dominates the global antibody drug conjugate contract manufacturing market. In terms of application, solid tumor applications account for more than half of the market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugates Contract Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugates Contract Manufacturing.
The Antibody Drug Conjugates Contract Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugates Contract Manufacturing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugates Contract Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Lonza Group
Merck KGaA
Recipharm
Thermo Fisher Scientific
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Curia
Novasep
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
Segment by Type
IgG1
IgG4
Segment by Application
Solid Tumors
Hematological Malignancies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Antibody Drug Conjugates Contract Manufacturing in global and regional level.
Chapter 3: Detailed analysis of Antibody Drug Conjugates Contract Manufacturing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody Drug Conjugates Contract Manufacturing revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Study Coverage
1.1 Antibody Drug Conjugates Contract Manufacturing Product Introduction
1.2 Market by Type
1.2.1 Global Antibody Drug Conjugates Contract Manufacturing Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 IgG1
1.2.3 IgG4
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugates Contract Manufacturing Market Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Solid Tumors
1.3.3 Hematological Malignancies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Antibody Drug Conjugates Contract Manufacturing Market Size Estimates and Forecasts
2.2 Antibody Drug Conjugates Contract Manufacturing Market Size by Region: 2023 Versus 2030
2.2.1 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Region: 2019-2024
2.2.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue Forecast by Region (2025-2030)
2.2.3 Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Region (2019-2030)
3 Global Antibody Drug Conjugates Contract Manufacturing by Company
3.1 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Company (2019-2024)
3.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue Share by Company (2019-2024)
3.3 Competitive Landscape
3.3.1 Key Antibody Drug Conjugates Contract Manufacturing Companies around the World: Ranking by Revenue
3.3.2 Global Antibody Drug Conjugates Contract Manufacturing Market Concentration Ratio (CR5 and HHI) & (2019-2024)
3.3.3 Global Antibody Drug Conjugates Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Antibody Drug Conjugates Contract Manufacturing Companies Headquarters & Product Type
3.4.1 Antibody Drug Conjugates Contract Manufacturing Companies Headquarters
3.4.2 Global Antibody Drug Conjugates Contract Manufacturing Companies Product & Service
3.4.3 Date of International Companies Enter into Antibody Drug Conjugates Contract Manufacturing Market
3.5 Global Antibody Drug Conjugates Contract Manufacturing Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Lonza Group
4.1.1 Lonza Group Company Information
4.1.2 Lonza Group Description, Business Overview
4.1.3 Lonza Group Antibody Drug Conjugates Contract Manufacturing Products Offered
4.1.4 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.1.5 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.1.6 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.1.7 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.1.8 Lonza Group Recent Developments
4.2 Merck KGaA
4.2.1 Merck KGaA Company Information
4.2.2 Merck KGaA Description, Business Overview
4.2.3 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Products Offered
4.2.4 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.2.5 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.2.6 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.2.7 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.2.8 Merck KGaA Recent Developments
4.3 Recipharm
4.3.1 Recipharm Company Information
4.3.2 Recipharm Description, Business Overview
4.3.3 Recipharm Antibody Drug Conjugates Contract Manufacturing Products Offered
4.3.4 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.3.5 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.3.6 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.3.7 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.3.8 Recipharm Recent Developments
4.4 Thermo Fisher Scientific
4.4.1 Thermo Fisher Scientific Company Information
4.4.2 Thermo Fisher Scientific Description, Business Overview
4.4.3 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Products Offered
4.4.4 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.4.5 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.4.6 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.4.7 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.4.8 Thermo Fisher Scientific Recent Developments
4.5 Abbvie
4.5.1 Abbvie Company Information
4.5.2 Abbvie Description, Business Overview
4.5.3 Abbvie Antibody Drug Conjugates Contract Manufacturing Products Offered
4.5.4 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.5.5 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.5.6 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.5.7 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.5.8 Abbvie Recent Developments
4.6 Piramal Pharma Solutions
4.6.1 Piramal Pharma Solutions Company Information
4.6.2 Piramal Pharma Solutions Description, Business Overview
4.6.3 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Products Offered
4.6.4 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.6.5 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.6.6 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.6.7 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.6.8 Piramal Pharma Solutions Recent Development
4.7 Catalent
4.7.1 Catalent Company Information
4.7.2 Catalent Description, Business Overview
4.7.3 Catalent Antibody Drug Conjugates Contract Manufacturing Products Offered
4.7.4 Catalent Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.7.5 Catalent Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.7.6 Catalent Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.7.7 Catalent Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.7.8 Catalent Recent Development
4.8 Sterling Pharma Solutions
4.8.1 Sterling Pharma Solutions Company Information
4.8.2 Sterling Pharma Solutions Description, Business Overview
4.8.3 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Products Offered
4.8.4 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.8.5 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.8.6 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.8.7 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.8.8 Sterling Pharma Solutions Recent Development
4.9 Curia
4.9.1 Curia Company Information
4.9.2 Curia Description, Business Overview
4.9.3 Curia Antibody Drug Conjugates Contract Manufacturing Products Offered
4.9.4 Curia Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.9.5 Curia Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.9.6 Curia Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.9.7 Curia Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.9.8 Curia Recent Development
4.10 Novasep
4.10.1 Novasep Company Information
4.10.2 Novasep Description, Business Overview
4.10.3 Novasep Antibody Drug Conjugates Contract Manufacturing Products Offered
4.10.4 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.10.5 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.10.6 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.10.7 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.10.8 Novasep Recent Development
4.11 Ajinomoto Bio-Pharma Services
4.11.1 Ajinomoto Bio-Pharma Services Company Information
4.11.2 Ajinomoto Bio-Pharma Services Description, Business Overview
4.11.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Products Offered
4.11.4 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.11.5 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.11.6 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.11.7 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.11.8 Ajinomoto Bio-Pharma Services Recent Development
4.12 BSP Pharmaceuticals
4.12.1 BSP Pharmaceuticals Company Information
4.12.2 BSP Pharmaceuticals Description, Business Overview
4.12.3 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Products Offered
4.12.4 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.12.5 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.12.6 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.12.7 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.12.8 BSP Pharmaceuticals Recent Development
4.13 Cerbios-Pharma
4.13.1 Cerbios-Pharma Company Information
4.13.2 Cerbios-Pharma Description, Business Overview
4.13.3 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Products Offered
4.13.4 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.13.5 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.13.6 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.13.7 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.13.8 Cerbios-Pharma Recent Development
4.14 Goodwin Biotechnology
4.14.1 Goodwin Biotechnology Company Information
4.14.2 Goodwin Biotechnology Description, Business Overview
4.14.3 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Products Offered
4.14.4 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.14.5 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.14.6 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.14.7 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.14.8 Goodwin Biotechnology Recent Development
5 Breakdown Data by Type
5.1 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
5.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue Forecast by Type (2025-2030)
5.3 Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
6.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue Forecast by Application (2025-2030)
6.3 Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Application (2019-2030)
7 North America
7.1 North America Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
7.2 North America Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Country (2019-2030)
7.3 North America Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
7.4 North America Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
8.2 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Region (2019-2030)
8.3 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
8.4 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
9 Europe
9.1 Europe Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
9.2 Europe Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Country (2019-2030)
9.3 Europe Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
9.4 Europe Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
10 Latin America
10.1 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
10.2 Latin America Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Country (2019-2030)
10.3 Latin America Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
10.4 Latin America Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
11.2 Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Country (2019-2030)
11.3 Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
11.4 Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Antibody Drug Conjugates Contract Manufacturing Supply Chain Analysis
12.2 Antibody Drug Conjugates Contract Manufacturing Key Raw Materials and Upstream Suppliers
12.3 Antibody Drug Conjugates Contract Manufacturing Clients Analysis
12.4 Antibody Drug Conjugates Contract Manufacturing Sales Channel and Sales Model Analysis
12.4.1 Antibody Drug Conjugates Contract Manufacturing Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Antibody Drug Conjugates Contract Manufacturing Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Antibody Drug Conjugates Contract Manufacturing Distributors
13 Market Dynamics
13.1 Antibody Drug Conjugates Contract Manufacturing Industry Trends
13.2 Antibody Drug Conjugates Contract Manufacturing Market Drivers
13.3 Antibody Drug Conjugates Contract Manufacturing Market Challenges
13.4 Antibody Drug Conjugates Contract Manufacturing Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer